Preventative Medication (PM)

Phase 1Small molecule

NNYU Langone Health

Preventative Medication (PM) is one of 4 small molecule programs targeting Focal Epilepsy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Focal EpilepsyRecruiting

Focal EpilepsyPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Focal Epilepsy

#DrugCompanyPhaseTrials

Benemid

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 2

XEN1101

XXenon Pharmaceuticals Inc.

Phase 3

1 3

BHV-7000

BBiohaven Therapeutics Ltd.

Phase 2

2 4

Preventative Medication (PM)

NNYU Langone Health

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Focal Epilepsy

NCT07012148

Clinical

Trials by Indication[1]

Migraine1 trial

Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department

Withdrawn·NNYU Langone Health·Phase 4·NCT02945839

Focal Epilepsy1 trial

FORESITE (FOREcasting Seizures to Initiate ThErapy): Optimizing Management of Drug-Resistant Epilepsy Using Seizure Forecasts Via Subscalp EEG and Wearables

Recruiting·MMayo Clinic·Phase 1·NCT07012148·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Preventative Medication (PM). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Preventative Medication (PM) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Preventative Medication (PM). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNYU Langone Health

Preventative Medication (PM)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Migraine1 trial

Focal Epilepsy1 trial

References

Drug Info

Quick Facts

Related News